Auxilart to Speak at BioProcess International Asia in October 2025

Auxilart Co., Ltd. (Headquarters: Tokyo; Japan, CEO: Junu Kim) announced today that Dr. Junu Kim, Chief Executive Officer, will be speaking at BioProcess International Asia 2025 on Tuesday, October 21, 2025, in Kyoto, Japan, alongside Dr. Hiroto Bando, President, Japan at Minaris Advanced Therapies. 

The presentation will explore how Auxilart’s mechanistic and hybrid modeling approaches enhance the analysis and design of pharmaceutical manufacturing processes. By leveraging predictive simulations, these methods provide deeper insight into cell culture dynamics, support model-based decision-making, and have demonstrated real-world efficiency gains, including potential labor cost reductions of up to 38%.

For registration, please visit: https://informaconnect.com/bpi-asia/

Session details: 

• Title: Modeling and Simulation for Enhanced Bioprocess Designin Mesenchymal Stromal Cell Cultivation  

• Date & Time: Tuesday, October 21, 2025 at 11:45 AM JST  

About BioProcess International Asia 2025 

BioProcess International Asia 2025 is a leading conference for biopharmaceutical professionals to share innovations and solutions in bioprocess development and manufacturing.

• Date: October 20–22, 2025 

• Location: Westin Miyako, Kyoto, Japan 

About Minaris Advanced Therapies

Minaris Advanced Therapies is a global contract development and manufacturing organization with a focus on cell and gene therapies and a contract testing provider.

Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 600,000 square feet of infrastructure across the United States, Europe and Asia. The organization has manufactured over 7,500 GMP batches and has a global network that supports therapy developers through early-stage development, clinical trials and commercial manufacturing.

For more information, visit Minaris Advanced Therapies Website.

About Auxilart

Auxilart Co., Ltd. provides advanced digital simulation solutions based on mechanistic models developed at the University of Tokyo, where the technology has been developed over a decade.

Our Mechanistic model-based simulation technology enables high-precision simulations with minimal data, using only 1% of the data typically required by AI-based methods. By replacing extensive physical experiments with digital simulations, we achieve up to 90% reduction in both cost and time while enhancing productivity.

Founded in 2023, Auxilart has already provided its solutions to Boehringer Ingelheim, Daiichi Sankyo and major Japanese pharmaceutical companies.

For more information, visit Auxilart Website.

Media Contact

Auxilart Co., Ltd.
Established: July 19, 2023
CEO: Junu Kim
Headquarters: 6F, 1-12-4 Ginza, Chuo-ku, Tokyo, Japan

Contact Person: Kay (Keisuke) Okita
Email: information@auxilart.com